Download App

Log in to access Online Inquiry
Company Overview More
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
CEO: Metzger M.B.A., Michael A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

SNDX Syndax Pharmaceuticals

14.560-0.100-0.68%
Close 05/23 20:00 ET
14.56000.00%
Post Mkt Price 05/23 16:30 ET
High
14.730
Open
14.730
Turnover
9.33M
Low
14.300
Pre Close
14.660
Volume
642.52K
Market Cap
818.74M
P/E(TTM)
39.35
52wk High
22.710
Shares
56.23M
P/E(Static)
31.65
52wk Low
13.270
Float Cap
661.37M
Bid/Ask %
-100.00%
Historical High
27.850
Shs Float
45.42M
Volume Ratio
1.54
Historical Low
3.390
Dividend TTM
--
Div Yield TTM
700
P/B
2.19
Dividend LFY
--
Div Yield LFY
4807.69%
Turnover Ratio
1.42%
Amplitude
2.93%
Avg Price
14.526
Lot Size
1
Float Cap
661.37M
Bid/Ask %
-100.00%
Historical High
27.850
Shs Float
45.42M
Volume Ratio
1.54
Historical Low
3.390
Dividend TTM
--
P/B
2.19
Dividend LFY
--
Turnover Ratio
1.42%
Amplitude
2.93%
Avg Price
14.526
Lot Size
1
Price Forecast

No Data

News

Comment